Profile data is unavailable for this security.
About the company
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.
- Revenue in USD (TTM)0.00
- Net income in USD-7.72m
- Incorporated2009
- Employees16.00
- LocationEdesa Biotech Inc100 Spy CrtMARKHAM L3R 5H6CanadaCAN
- Phone+1 (905) 475-1234
- Fax+1 (905) 475-1234
- Websitehttps://www.edesabiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Check Cap Ltd | 0.00 | -17.62m | 13.22m | 85.00 | -- | 0.4826 | -- | -- | -3.01 | -3.01 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -44.86 | -58.80 | -48.21 | -66.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.08 | -- | 16.04 | -- |
| Tonix Pharmaceuticals Holding Corp | 7.77m | -116.66m | 13.27m | 103.00 | -- | 0.0872 | -- | 1.71 | -8.62 | -8.62 | 0.4572 | 1.80 | 0.0409 | -- | -- | 75,417.48 | -61.38 | -59.46 | -68.01 | -65.92 | 38.97 | -- | -1,501.78 | -5,126.73 | 1.81 | -- | 0.0779 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
| Senti Biosciences Inc | 2.56m | -92.72m | 13.27m | 48.00 | -- | 0.1981 | -- | 5.18 | -2.09 | -1.60 | 0.0577 | 1.46 | 0.0171 | -- | 6.94 | 53,354.17 | -61.76 | -- | -68.80 | -- | -- | -- | -3,620.54 | -- | -- | -- | 0.0015 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -13.04m | 13.39m | 12.00 | -- | 0.6432 | -- | -- | -2.98 | -2.98 | 0.00 | 0.7929 | 0.00 | -- | -- | 0.00 | -77.27 | -70.52 | -91.06 | -81.86 | -- | -- | -- | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 260.50k | -19.03m | 13.60m | 8.00 | -- | 1.18 | -- | 52.21 | -3.62 | -3.62 | 0.0489 | 1.77 | 0.0132 | -- | 13.06 | 32,562.50 | -96.49 | -66.49 | -117.79 | -85.55 | -- | -- | -7,304.76 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Nexgel Inc | 4.09m | -3.16m | 13.76m | 19.00 | -- | 2.70 | -- | 3.37 | -0.5566 | -0.5566 | 0.7212 | 0.818 | 0.4027 | 3.81 | 9.57 | 215,263.20 | -31.39 | -44.61 | -38.80 | -56.19 | 15.16 | 5.02 | -77.95 | -180.98 | 1.46 | -- | 0.1396 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| NanoViricides Inc | 0.00 | -9.36m | 13.84m | 7.00 | -- | 1.20 | -- | -- | -0.8004 | -0.8004 | 0.00 | 0.9828 | 0.00 | -- | -- | 0.00 | -55.47 | -43.54 | -57.90 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Edesa Biotech Inc | 0.00 | -7.72m | 14.02m | 16.00 | -- | 2.36 | -- | -- | -2.60 | -2.60 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -79.13 | -- | -95.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Cell MedX Corp | 70.00 | -96.91k | 14.27m | 0.00 | -- | -- | -- | 203,819.20 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
| Trinity Biotech plc (ADR) | 56.83m | -36.87m | 14.37m | 398.00 | -- | -- | -- | 0.2528 | -17.71 | -9.31 | 12.36 | -15.67 | 0.7501 | 1.76 | 3.83 | -- | -48.66 | -19.82 | -61.89 | -28.84 | 34.22 | 39.90 | -64.88 | -28.30 | 1.27 | -1.61 | 1.77 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
| Enzolytics Inc | 0.00 | -119.19k | 14.44m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.77m | -2.63m | 14.99m | 30.00 | -- | 1.55 | -- | 1.53 | -0.1389 | -0.1389 | 0.6873 | 0.5466 | 0.9703 | 7.98 | 5.33 | -- | -26.11 | -3.83 | -31.86 | -5.02 | 13.61 | 14.55 | -26.91 | -3.04 | 4.24 | -186.19 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
| Ibio Inc | 50.00k | -20.77m | 15.07m | 26.00 | -- | 0.6243 | -- | 301.44 | -21.91 | -27.30 | 0.0437 | 2.84 | 0.0012 | -- | 0.0129 | 1,923.08 | -48.41 | -28.09 | -113.84 | -32.63 | -- | -- | -41,546.00 | -1,467.30 | -- | -518.33 | 0.5942 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| Holder | Shares | % Held |
|---|---|---|
| CM Management LLCas of 31 Dec 2023 | 62.00k | 1.96% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 15.70k | 0.50% |
| Geode Capital Management LLCas of 31 Dec 2023 | 14.68k | 0.46% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 11.33k | 0.36% |
| UBS Securities LLCas of 31 Dec 2023 | 4.28k | 0.14% |
| Tower Research Capital LLCas of 31 Dec 2023 | 1.56k | 0.05% |
| Vanguard Global Advisers LLCas of 31 Dec 2023 | 643.00 | 0.02% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Dec 2023 | 217.00 | 0.01% |
| Dimensional Fund Advisors Ltd.as of 31 May 2023 | 157.00 | 0.01% |
| TD Waterhouse Canada, Inc.as of 31 Dec 2023 | 142.00 | 0.00% |
